Business Advisor:
Guiding Our Strategies to Advance Transformative Drugs

Our Business Advisor provides partnership and licensing strategies to advance our transformative ChaESAR portfolio.

Dr. David P Brooks, Ph.D., FAHA, FAPS

Dr. David Brooks is an experienced and accomplished pharmaceutical executive and scientist with a strong track record in both business development and drug research and development. He is CEO and Founder of Brooks Pharma Consulting, LLC.

Show More

Previously, David spent over thirty-three years in the pharmaceutical industry including 22 years at GSK where he was Vice President of Cardiovascular and Urology Drug Discovery and 11 years at J&J where he was Senior Director of Immunology Business Development & Licensing. His successful track record in business development includes numerous deals representing over $6B in deal terms for the in-licensing or out-licensing of various drug candidates and platform technologies.

David contributed to the discovery and development of three approved drugs, and he has over 200 publications. Dr. Brooks is a graduate of the University of London (B.Sc.) and the University of Southampton (M.Sc., PH.D.).  He is a Fellow of the American Heart Association and the American Physiological Society.

Show Less

What Makes ChaESAR™ Compelling?

See how we’re building on the modern science of RNA and our novel technology to develop saRNA therapies that can achieve superior patient response at a lower dose.

About Self-Amplifying RNA